Blood markers may predict drug resistance in rare blood cancer
NCT ID NCT05853458
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 31 times
Summary
This study looked at whether two simple blood test results—hemoglobin and red blood cell distribution width—can predict if a person with polycythemia vera will stop responding to the drug hydroxyurea. Researchers used a computer model to identify these markers and then tested them in 76 patients starting treatment. The goal was to help doctors choose better treatments earlier for those likely to fail standard therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POLYCYTHEMIA VERA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Heidelberg, Baden-Wurttemberg, 69115, Germany
-
Novartis Investigative Site
Kronach, Bavaria, 96317, Germany
-
Novartis Investigative Site
Straubing, Bavaria, 94315, Germany
-
Novartis Investigative Site
Langen, Hesse, 63225, Germany
-
Novartis Investigative Site
Lingen Ems, Lower Saxony, 49808, Germany
-
Novartis Investigative Site
Aachen, North Rhine-Westphalia, 52064, Germany
-
Novartis Investigative Site
Cologne, North Rhine-Westphalia, 50674, Germany
-
Novartis Investigative Site
Dortmund, North Rhine-Westphalia, 44309, Germany
-
Novartis Investigative Site
Velbert, North Rhine-Westphalia, 42551, Germany
-
Novartis Investigative Site
Saarbrücken, Saarland, 66113, Germany
-
Novartis Investigative Site
Merseburg, Saxony-Anhalt, 06217, Germany
-
Novartis Investigative Site
Berlin, 10407, Germany
-
Novartis Investigative Site
Donauwörth, 86609, Germany
-
Novartis Investigative Site
Dresden, 01307, Germany
-
Novartis Investigative Site
Erding, 85435, Germany
-
Novartis Investigative Site
Gütersloh, 33332, Germany
-
Novartis Investigative Site
Hanover, 30161, Germany
-
Novartis Investigative Site
Kiel, 24105, Germany
-
Novartis Investigative Site
Mutlangen, 73557, Germany
-
Novartis Investigative Site
Naunhof, 04683, Germany
-
Novartis Investigative Site
Würselen, 52146, Germany
Conditions
Explore the condition pages connected to this study.